Nventa Biopharmaceuticals Corporation is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). One of the most common sexually transmitted diseases in the world, HPV infects an estimated 80 percent of sexually active men and women at some point in their lives.

The Company’s lead candidate, HspE7, is a novel therapeutic vaccine intended for the treatment of HPV-related diseases. HspE7 is derived from Nventa’s proprietary CoVal™ fusion platform that uses recombinant DNA technology to covalently fuse heat shock proteins to target antigens, thereby stimulating cellular immune system responses to specific diseases. Nventa is developing HspE7 in combination with Poly-ICLC, an adjuvant that activates innate immunity, for multiple indications.

Nventa has a strong and growing global patent portfolio protecting its proprietary technology, including its HspE7 candidate and applications of its CoVal™ technology in the treatment of hepatitis B, herpes simplex virus, HIV and influenza.

Headquartered in San Diego, CA, Nventa Common Stock trades on the Toronto Stock Exchange (TSX) under the symbol: NVN.